Shares of H-CYTE, Inc. (OTCMKTS:HCYTD – Get Free Report) dropped 49.5% on Tuesday . The company traded as low as $2.02 and last traded at $2.02. Approximately 400 shares traded hands during trading, an increase of 288% from the average session volume of 103 shares. The stock had previously closed at $4.00.
H-CYTE Price Performance
The stock’s 50 day simple moving average is $2.02 and its two-hundred day simple moving average is $2.02.
About H-CYTE
H-CYTE, Inc, a biopharmaceutical company, develops and delivers various treatments for patients with chronic respiratory and pulmonary disorders in the United States. The company develops and implements treatment options in autologous cellular therapy to treat chronic lung disorders. It has a product supply agreement with Rion, LLC to develop and distribute a biologic for chronic obstructive pulmonary disease. The company is headquartered in Tampa, Florida.
Featured Articles
- Five stocks we like better than H-CYTE
- PriceSmart Stock Eyes $220 as Chile Expansion Fuels Growth
- Dollar Tree’s Turnaround Is Starting to Take Root
- Why Levi’s Digital Strategy Is Paying Off in a Big Way
- Constellation Brands: Beer Growth and Buybacks Mask Stock’s Slump
Receive News & Ratings for H-CYTE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for H-CYTE and related companies with MarketBeat.com's FREE daily email newsletter.
